M
591.02
46.61 (8.56%)
| Previous Close | 544.41 |
| Open | 552.42 |
| Volume | 889,146 |
| Avg. Volume (3M) | 342,995 |
| Market Cap | 13,422,904,320 |
| Price / Sales | 17.11 |
| Price / Book | 20.74 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.5 |
| Average | -1.00 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 900.00 (Piper Sandler, 52.28%) | Buy |
| Median | 630.00 (6.60%) | |
| Low | 445.00 (B of A Securities, -24.71%) | Hold |
| Average | 629.88 (6.58%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 526.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 19 Dec 2025 | 900.00 (52.28%) | Buy | 591.02 |
| 15 Oct 2025 | 540.00 (-8.63%) | Buy | 433.45 | |
| B. Riley Securities | 11 Dec 2025 | 670.00 (13.36%) | Buy | 571.33 |
| 29 Sep 2025 | 560.00 (-5.25%) | Buy | 443.10 | |
| HC Wainwright & Co. | 21 Nov 2025 | 620.00 (4.90%) | Buy | 547.96 |
| 11 Nov 2025 | 568.00 (-3.89%) | Buy | 541.50 | |
| Oppenheimer | 20 Nov 2025 | 650.00 (9.98%) | Buy | 542.12 |
| 10 Oct 2025 | 590.00 (-0.17%) | Buy | 429.60 | |
| Truist Securities | 19 Nov 2025 | 640.00 (8.29%) | Buy | 555.60 |
| 15 Oct 2025 | 580.00 (-1.86%) | Buy | 433.45 | |
| Canaccord Genuity | 13 Nov 2025 | 587.00 (-0.68%) | Buy | 514.93 |
| Citizens | 05 Nov 2025 | 527.00 (-10.83%) | Buy | 475.87 |
| B of A Securities | 03 Nov 2025 | 445.00 (-24.71%) | Hold | 412.35 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FRIEDMAN PAUL A | - | 552.47 | -24,800 | -13,701,256 |
| TAUB REBECCA | - | 552.47 | -24,105 | -13,317,289 |
| Aggregate Net Quantity | -48,905 | |||
| Aggregate Net Value ($) | -27,018,545 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 552.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TAUB REBECCA | Director | 10 Dec 2025 | Automatic sell (-) | 18,650 | 552.47 | 10,303,566 |
| TAUB REBECCA | Director | 10 Dec 2025 | Disposed (-) | 5,455 | 552.47 | 3,013,724 |
| TAUB REBECCA | Director | 10 Dec 2025 | Option execute | 18,650 | - | - |
| FRIEDMAN PAUL A | Director | 10 Dec 2025 | Automatic sell (-) | 24,800 | 552.47 | 13,701,256 |
| FRIEDMAN PAUL A | Director | 10 Dec 2025 | Option execute | 24,800 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |